Lebrikizumab Shows Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis

Strategic Insights -

Fresh data on Skin Diseases and Conditions - Atopic Dermatitis has been presented in a new report from Milan, Italy. The research, conducted by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, aimed to investigate the effectiveness and safety of lebrikizumab, a biologic drug targeting interleukin-13, in a predominantly white adult population. The study, involving 78 patients with moderate-to-severe atopic dermatitis, demonstrated significant benefits in disease severity, quality of life, and mental health after 16 weeks of treatment.

Key Takeaways:

  • The study demonstrated the efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis, showing significant benefits in disease severity, quality of life, and mental health.
  • The research involved a 16-week retrospective multicenter study with 78 adult patients from a predominantly white cohort, making it one of the first real-world multicenter studies in a predominantly adult white population.
  • Lebrikizumab treatment improved symptoms, quality of life, and mental health in both biologic-naive and experienced patients with atopic dermatitis.
  • The study used a range of outcome measures, including the Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), itch- and sleep-numberical rating scales (NRS), and Hospital Anxiety and Depression Scales.
  • The research has significant implications for the treatment of moderate-to-severe atopic dermatitis, particularly in predominantly white adult populations.

Statistics:

  • 78 adult patients participated in the study, with 45.5% being biologic-naive and 54.5% being biologic-experienced.
  • The study reported a mean EASI score of - 15.8 ± 9.4 at week 16, representing a significant reduction in disease severity.
  • 71.8% of patients achieved minimal disease activity (MDA) at week 16.
  • The study showed significant improvements in quality of life (p < 0.001) and mental health status (p < 0.01) after 16 weeks of lebrikizumab treatment.

Sources:

  • Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study. Dermatology and Therapy, 2025.
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. Via Pace, 9, 20122, Milan, Italy.
  • Gianluca Avallone, Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.